Navigation Links
Sunshine pill for prostate cancer in 2009

A tablet designed to emulate the healing power of the sun could be available for the treatment of advanced prostate cancer as early as 2009. But it remains to be seen whether the drug will be the revolution in prostate cancer care that its makers claim.

The drug, Asentar (DN-101), is based on vitamin D and is given to patients in the advanced stages of prostate cancer along with chemotherapy drugs. Drug makers came up with the idea because vitamin D from sunlight improves the prognosis of certain cancers. But taking natural levels of the vitamin has no effect. Novacea, the company that makes Asentar, produced a novel formulation that reproduces the healing effect without the dangerous side-effects of a vitamin D overdose. If the on-going phase III trial goes to plan, the new drug should be available in 2009, reports Chemistry & Industry, the magazine of the SCI.

'If the results of the phase III trial are as good as those of the phase II trial, that would be significant,' says Nick James, professor of oncology at the University of Birmingham. In the phase II trials, Asentar significantly improved survival rates, 9 months over patients taking chemotherapy drugs (taxotere) alone. 'On average, patients in the advanced stage of the disease survive about 18 months, so an extension of 9 months would be very significant in my view,' says James.

Asentar provides levels of vitamin D 50-100 times higher than normal. Patients would be expected to take one tablet once a week with their weekly regime of taxotere for three weeks out of every four.

Business analysts say Asentar is a potential blockbuster, because prostate cancer rates are expected to soar in the next few years. But James is not so sure. 'A confounding factor is that if you go looking for more cases of cancer, you will find them. But this does not give you an accurate estimate of how many people will go on to develop advanced disease. In fact death rates are going down, which means that the market for this drug is probably pretty static.'

James also points out that it is far from certain that the Phase III trials will repeat the success of early trials. 'The phase II trial used a less than optimal taxotere regime so the survival rate may have been artificially inflated,' he says. He points out, however, that it may be that the Asentar will eventually prove applicable in the earlier stages of the disease.

Prostate cancer is the second leading cause of cancer death in men. Prostate cancer kills one man every hour in the UK.
'"/>

Source:Society of Chemical Industry


Related biology news :

1. Mitochondrial DNA mutations play significant role in prostate cancer
2. Weizmann Institute scientists develop a new approach for directing treatment to metastasized prostate cancer in the bones.
3. Test for early detection of prostate cancer shows promise
4. U-M researchers identify new blood test for prostate cancer
5. U-M scientists say fused genes trigger the development of prostate cancer
6. Virus chip detects new virus in prostate tumors
7. Human prostate grown from embryonic stem cells
8. Curry and cauliflower could halt prostate cancer
9. Macrophage signaling may affect hormone resistance in prostate tumors
10. Markers of gene, protein, or micro-RNA activity predict outcome in prostate and colorectal cancers
11. Vegetables inhibit growth of prostate cancer in mice with human tumors

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... for financial services, but it also plays a fundamental part ...
(Date:4/26/2016)... April 27, 2016 Research ... Multi-modal Biometrics Market 2016-2020"  report to their offering.  ... The analysts forecast the global multimodal ... 15.49% during the period 2016-2020.  Multimodal ... sectors such as the healthcare, BFSI, transportation, automotive, ...
Breaking Biology News(10 mins):
(Date:5/25/2016)... ... May 25, 2016 , ... The American Medical Informatics Association ... the National Coordinator for Health IT (ONC) outlining a measurement approach to interoperability ... available when and where it was needed. The organization of health informatics professionals ...
(Date:5/25/2016)... ... May 25, 2016 , ... Lady had been battling arthritis since the ... in her left knee. Lady’s owner Hannah sought the help of Dr Jeff Christiansen ... to repair her cruciate ligament and help with the pain of Lady’s arthritis. Dr ...
(Date:5/24/2016)...   MedyMatch Technology Ltd ., the data analytics healthcare ... support tools in the emergency room, announced today that it ... Technology Industries (IATI) BioMed Conference. The Conference ... National Life Sciences and Technology Week, and is being held ... Tel Aviv, Israel . Gene Saragnese ...
(Date:5/23/2016)... ... ... blood donations in South Texas and across the nation is growing. , But according to ... are on the decline. In fact, donations across the country are at their lowest point ... the last four years alone. , There is no substitute for blood. , “We want ...
Breaking Biology Technology: